Comparison Overview

MAST Biosurgery

VS

Medline Industries, LP

MAST Biosurgery

6749 Top Gun Street, Ste 108, San Diego, CA, 92121, US
Last Update: 2025-05-04 (UTC)
Between 800 and 900

Strong

Leading in the design, development, and production of bioresorbable polymer implants, and emerging new technologies for the use in variety of surgical applications within the biosurgery market. Before the advent of bioresorbable materials, the closure of soft tissue was limited to permanent materials such as nylon sutures. Advances in material sciences led to the development of bioresorbable polymer sutures that met the clinical needs of holding soft tissues together, while serving the patient's need of not remaining permanently in the body. The evolution of bioresorbable polymer technology facilitated the development of large bioresorbable polymer sheets that could span large tissue masses and subsequently hold them in place. The thin sheets facilitate the healing of larger tissue masses and virtually eliminating many adverse effects of permanent implants. Bioresorbable surgical thin sheet for soft tissue applications, made from polylactide (PLA): a copolymer of 70:30 Poly(L-lactide-co-D,L-lactide). Composed of lactic acid similar to that which occurs naturally in the human body, the copolymer maintains its strength during the healing process, and through hydrolysis slowly breaks down into lactic acid molecules. The molecules are ultimately metabolized into carbon dioxide and water and are released from the body through the lungs.

NAICS: 3391
NAICS Definition: Medical Equipment and Supplies Manufacturing
Employees: 18
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Medline Industries, LP

Three Lakes Drive, Northfield, IL, 60093, US
Last Update: 2025-03-04 (UTC)

Strong

Between 800 and 900

Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its unique offering of world-class products, supply chain resilience and clinical practice expertise, Medline delivers improved clinical, financial and operational outcomes. Headquartered in Northfield, Illinois, the company employs 43,000 people worldwide and operates in over 100 countries and territories. To learn more about how Medline makes healthcare run better, visit www.medline.com.

NAICS: 3391
NAICS Definition: Medical Equipment and Supplies Manufacturing
Employees: 16,474
Subsidiaries: 10
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/defaultcompany.jpeg
MAST Biosurgery
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
https://images.rankiteo.com/companyimages/medline-industries.jpeg
Medline Industries, LP
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
Compliance Summary
MAST Biosurgery
100%
Compliance Rate
0/4 Standards Verified
Medline Industries, LP
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Medical Equipment Manufacturing Industry Average (This Year)

No incidents recorded for MAST Biosurgery in 2025.

Incidents vs Medical Equipment Manufacturing Industry Average (This Year)

No incidents recorded for Medline Industries, LP in 2025.

Incident History โ€” MAST Biosurgery (X = Date, Y = Severity)

MAST Biosurgery cyber incidents detection timeline including parent company and subsidiaries

Incident History โ€” Medline Industries, LP (X = Date, Y = Severity)

Medline Industries, LP cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/defaultcompany.jpeg
MAST Biosurgery
Incidents

No Incident

https://images.rankiteo.com/companyimages/medline-industries.jpeg
Medline Industries, LP
Incidents

No Incident

FAQ

Both MAST Biosurgery company and Medline Industries, LP company demonstrate a comparable AI risk posture, with strong governance and monitoring frameworks in place.

Historically, Medline Industries, LP company has disclosed a higher number of cyber incidents compared to MAST Biosurgery company.

In the current year, Medline Industries, LP company and MAST Biosurgery company have not reported any cyber incidents.

Neither Medline Industries, LP company nor MAST Biosurgery company has reported experiencing a ransomware attack publicly.

Neither Medline Industries, LP company nor MAST Biosurgery company has reported experiencing a data breach publicly.

Neither Medline Industries, LP company nor MAST Biosurgery company has reported experiencing targeted cyberattacks publicly.

Neither MAST Biosurgery company nor Medline Industries, LP company has reported experiencing or disclosing vulnerabilities publicly.

Medline Industries, LP company has more subsidiaries worldwide compared to MAST Biosurgery company.

Medline Industries, LP company employs more people globally than MAST Biosurgery company, reflecting its scale as a Medical Equipment Manufacturing.

Latest Global CVEs (Not Company-Specific)

Description

An issue was discovered in chinabugotech hutool before 5.8.4 allowing attackers to execute arbitrary expressions that lead to arbitrary method invocation and potentially remote code execution (RCE) via the QLExpressEngine class.

Description

A weakness has been identified in JeecgBoot up to 3.8.2. The impacted element is an unknown function of the file /sys/role/exportXls. This manipulation causes improper authorization. It is possible to initiate the attack remotely. The exploit has been made available to the public and could be exploited. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 4.0
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:N/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A security flaw has been discovered in JeecgBoot up to 3.8.2. The affected element is an unknown function of the file /sys/user/exportXls of the component Filter Handler. The manipulation results in improper authorization. The attack may be performed from remote. The exploit has been released to the public and may be exploited. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 4.0
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:N/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A vulnerability was identified in JeecgBoot up to 3.8.2. Impacted is an unknown function of the file /sys/tenant/deleteBatch. The manipulation of the argument ids leads to improper authorization. The attack is possible to be carried out remotely. The complexity of an attack is rather high. The exploitability is considered difficult. The exploit is publicly available and might be used. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 2.1
Severity: HIGH
AV:N/AC:H/Au:S/C:P/I:N/A:N
cvss3
Base: 3.1
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 2.3
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A vulnerability was determined in JeecgBoot up to 3.8.2. This issue affects some unknown processing of the file /api/getDepartUserList. Executing manipulation of the argument departId can lead to improper authorization. The attack can be executed remotely. This attack is characterized by high complexity. The exploitability is assessed as difficult. The exploit has been publicly disclosed and may be utilized. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 2.1
Severity: HIGH
AV:N/AC:H/Au:S/C:P/I:N/A:N
cvss3
Base: 3.1
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 2.3
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X